Pharma & APIs
Critical node· Pharma & APIs · Critical anchor

Generic APIs, China & India

Taizhou (Zhejiang), China28.66°N 121.42°E
computed criticality22/100
reading
China + India ≈66% of generic APIs (volume); ≈22.6% of EU API imports come from China
2024
Fault line

About two-thirds of the world's generic active ingredients are made in China and India, the latter formulating finished products from Chinese materials. By volume, China directly supplies only 8% of the APIs in American drugs, but its real grip on the generic chain approaches 80% once intermediates synthesised from Chinese KSM are counted. This concentration of a low-margin market discourages any return of capacity to the West.

Actors
Zhejiang Pharmaceutical
Aurobindo Pharma (Hyderabad)
Zhejiang Huahai (Linhai)
Depends on 3
6-APA & antibiotics, ChinaPharma & APIs · Critical anchorKSM & API, India (Hyderabad)Pharma & APIs · LinkPharma vitamins, China (Zhejiang NHU)Pharma & APIs · Link
Feeds 2
Drug shortages, FDA / EMA / WHOPharma & APIsPort of Shanghai, YangshanChokepoints
Sources